{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T10:45:08Z","timestamp":1694947508038},"reference-count":26,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T00:00:00Z","timestamp":1541376000000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Vitiligo ist eine erworbene Hauterkrankung, an der weltweit 0,5\u00a0% der Bev\u00f6lkerung erkranken und die eine gro\u00dfe Herausforderung in der dermatologischen Versorgung darstellt. Die Erkrankung geht f\u00fcr Betroffene oftmals aufgrund der fleckigen Depigmentierung mit einer kosmetischen Entstellung und gro\u00dfem Leidensdruck einher. Pathophysiologisch werden als Hauptursachen f\u00fcr den Verlust funktionierender Melanozyten eine genetische Pr\u00e4disposition, autoimmune Mechanismen und oxidativer Stress angesehen. Vorgestellt werden die Therapieempfehlungen der europ\u00e4ischen Leitlinie in Erg\u00e4nzung mit Empfehlungen aus aktuellen \u00dcbersichtsarbeiten zu Vitiligo. Bisherige therapeutische Optionen greifen auf drei Wegen: <jats:italic>(1.)<\/jats:italic> Regulation der Autoimmunantwort mit topischen und systemischen immunmodulierenden Pharmaka (Kortikosteroide und Calcineurininhibitoren), <jats:italic>(2.)<\/jats:italic> Reduktion des melanozyt\u00e4ren, oxidativen Stress mittels topischer und systemischer Antioxidantien sowie <jats:italic>(3.)<\/jats:italic> Aktivierung der Melanozytenregeneration durch Phototherapie (v.\u00a0a. UVB) und Transplantation von pigmentierten Zellen. Dar\u00fcber hinaus sollten dem Patienten Techniken zur Camouflage angeboten werden. Nach erfolgreicher Repigmentierung ist eine Rezidivprophylaxe mit Calcineurininhibitoren sinnvoll. Kombinationstherapien oben genannter Therapieans\u00e4tze werden generell als erfolgreicher angesehen als Monotherapien. Auch ist ein m\u00f6glichst fr\u00fcher Therapiebeginn prognostisch g\u00fcnstig. Mit Hilfe der genannten Therapieans\u00e4tze kann es gelingen das Fortschreiten der Erkrankung aufzuhalten, depigmentierte Herde zu stabilisieren und eine Repigmentierung zu erreichen. Nur in Ausnahmef\u00e4llen kommt eine dauerhafte Depigmentierung in Frage. Weiterreichende Erkenntnisse zur Pathogenese der Erkrankung lassen auf neue Therapieans\u00e4tze hoffen.<\/jats:p>","DOI":"10.1111\/ddg.13680_g","type":"journal-article","created":{"date-parts":[[2018,11,5]],"date-time":"2018-11-05T14:22:25Z","timestamp":1541427745000},"page":"1309-1314","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutisches Management bei Vitiligo"],"prefix":"10.1111","volume":"16","author":[{"given":"Rachela","family":"Bleuel","sequence":"first","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Dermatologie und Allergologie am Biederstein Technische Universit\u00e4t M\u00fcnchen"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernadette","family":"Eberlein","sequence":"additional","affiliation":[{"name":"Klinik und Poliklinik f\u00fcr Dermatologie und Allergologie am Biederstein Technische Universit\u00e4t M\u00fcnchen"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,11,5]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60763-7"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0749.2003.00032.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2016.00003"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12492612"},{"key":"e_1_2_6_6_1","first-page":"5","article-title":"Recent advances in understanding vitiligo","author":"Manga P","year":"2016","journal-title":"F1000Res"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2016.11.005"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.10.044"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-148X.2012.00997.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12186"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.08.063"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2010.01139.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.144144"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11197.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.09.034"},{"key":"e_1_2_6_16_1","first-page":"987","article-title":"Development and validation of the Vitiligo Extent Score (VES): an international collaborative initiative","volume":"136","author":"Geel N","year":"2016","journal-title":"J Invest Dermatol"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2016.11.014"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2016.11.007"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.1999.00623.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2000.00006.x"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2016.11.012"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2016.11.008"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2014.1875"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2016.11.009"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2016.11.010"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.527"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.010"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fddg.13680_g","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.13680_g","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T15:51:19Z","timestamp":1694879479000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.13680_g"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1111\/ddg.13680_g"],"URL":"https:\/\/doi.org\/10.1111\/ddg.13680_g","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"2018-01-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}